This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Oxford-based machine learning start-up Etcembly secures Private Seed Funding

Oxford-based machine learning start-up Etcembly secures Private Seed Funding

23 Apr 2021

Oxford-based machine learning start-up Etcembly secures Private Seed Funding Updated: Apr 23 Oxford, UK: 23rd April 2021. No embargo. Etcembly Ltd (Etcembly), a company building a platform to decode immune repertoires in health and disease, has closed an oversubscribed seed round with a group of private investors. The founders of Etcembly, Michelle Teng, CEO, and Jacob Hurst, CTO, bring a unique blend of... Read more

New ATDBio grant to improve oligonucleotide synthesis for COVID-19 tests

New ATDBio grant to improve oligonucleotide synthesis for COVID-19 tests

13 Apr 2021

Innovate UK funding as company invests in pandemic-driven expansion 13 APR 2021 ATDBio, a leader in complex oligonucleotide synthesis, has been awarded funding by Innovate UK to develop a new method for rapid, efficient and automatable production of large quantities of oligonucleotides for COVID-19 testing. The £168,130 grant, Improved oligonucleotide synthesis for faster, more accurate COVID-19 testing, will enable the company to... Read more

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

09 Apr 2021

Company’s technologies and drug-hunting expertise now responsible for world’s first and second AI-designed drugs to enter Phase I testing Exscientia, a leading artificial intelligence (AI) driven pharmatech company, today announced the first AI-designed molecule for immuno-oncology to enter human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed... Read more

Oxford Endovascular raises $10m to develop origami engineered device to prevent brain haemorrhage

Oxford Endovascular raises $10m to develop origami engineered device to prevent brain haemorrhage

08 Apr 2021

Funding will support the company to achieve first-in-human data Oxford, UK, 8th April 2021 – Oxford Endovascular, a pioneering British MedTech company and spinout from Oxford University, is developing a treatment for brain aneurysms, that will overcome challenges with existing medical devices. It has just raised $10m in a series A funding round. The funding which was conducted in Pounds Sterling includes a £3m investment from new investors... Read more

Sitryx appoints Pierre Legault as Chairman of its Board of Directors

Sitryx appoints Pierre Legault as Chairman of its Board of Directors

24 Mar 2021

Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces the appointment of Pierre Legault BAA, MBA, CA, CPA as Chairman of its Board of Directors. Mr. Legault is a renowned industry leader with over 35 years’ international experience in leading biopharmaceutical companies. Neil Weir, Chief Executive Officer of Sitryx, said:... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More